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Objectives: The guidelines of American Thyroid Association (ATA) 2011 recom-
mends in hypothyroid women receiving levothyroxine (LT4) and in untreated 
women with subclinical hypothyroidism and/or positive TPOAb (antibodies 
against thyroid peroxidase) regular laboratory check-up every 4 weeks during the 
1st half of pregnancy and at least once between 26th–32th weeks of gravidity. Our 
aim was to verify whether thyroid check-up between 26th–32thgestation weeks 
is beneficial in terms of LT4 dosage changes. MethOds: We performed a retro-
spective cross-sectional study in 2004–2014 in the Departments of Endocrinology 
of a university hospital and with laboratory assessment in a single center. The 
study included 188 women positively screened for hypothyroidism and/or positive 
TPOAb in first trimester of pregnancy. They were followed and examined according 
to the recommended algorithm by ATA 2011. We assessed serum concentrations 
of TSH, FT4 and TPOAb and evaluated changes of LT4 dosage with regard to week 
of laboratory check-up. Finally, we calculated direct medical costs per LT4 dosage 
change. Results: Of the 188 positively screened women in the first trimester, 104 
(55.3%) were hypothyroid and 84 (44.7%) were euthyroid but TPOAb positive. Overall, 
104 women (55.3%) undergo three laboratory check-ups, 57 (30.3%) four check-ups 
and 27(14.4%) five check-ups. The median entrance dose of LT4 was 50ug/day (range 
0 –170ug/day). The Laboratory check-up between 26th–32th gestation weeks led 
to LT4 dosage change in 18/132 (13.6%) women comparison to 131/167 (35.7%) in 
10th week, 55/142 (38.7%) in 14th week and 43/165 (26.1%) in 20th gestation weeks 
(p< 0.001). Average costs per LT4 dose change per women were 34.71EUR in 10th 
week, 47.01EUR in 14th week, 65.01EUR in 20th week and 127.53EUR in 30thgesta-
tion weeks. cOnclusiOns: Thyroid check-up between 26th–32th gestation weeks 
in women with hypothyroidism and/or positive TPOAb seems to be redundant in 
terms of LT4 dosage changes and produces inadequate high costs.
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Objectives: The transfers of nursing home (NH) residents to the emergency depart-
ments (ED) is costly for the healthcare systems. In this regard, the cost-analysis 
can be a useful tool to provide evidence-based information to guide resource allo-
cation. In this study, we analyze the cost at different stages of the transitions for 
Edmonton, Alberta, in Canada and evaluate the extent to which nursing home 
attributes, patients’ characteristics, and the transfers’ outcomes are significantly 
associated with the transfers cost. MethOds: We used a representative data col-
lected in 2011 from 398 residents and 28 nursing homes in Edmonton, Alberta from 
multiple levels and sources (facility, residents, healthcare providers, health records, 
administrative databases, etc.). We conducted a preliminary study to describe the 
costs at different stages of the transitions. Statistical modeling was used to identify 
any significant predictors of the transfers cost and estimate the magnitude of their 
impact. We investigated the ordinary least squares (OLS) models, the GLM, and the 
mixed effects regression models for clustered data. Models are assessed based on 
standard goodness-of-fit tests. Results: We find that hospitalization represents 
48% of the transfers total cost, whilst the emergency-department nursing cost 
and the nursing-home cost account for 26% and 10% respectively. The emergency-
Medical-Services account for 10%, and the diagnostic cost represents 3%. The physi-
cians plus consultations and the treatment costs represent 2% each. The estimation 
results show that sociodemographic factors, health characteristics, communication 
of information, healthcare providers’ involvement in the decision, the nature of the 
transfer coordinator, and providing medical care in the nursing home are significant 
predictors of the transfers cost. cOnclusiOns: The results of this analysis may fit 
into a subsequent cost-effectiveness analysis for the transfers cost.
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Objectives: Genotyping for the cytochrome P450-2D6 has the potency to predict 
differences in metabolism of nortriptyline. This information could optimize treat-
ment. We explored if possible benefits could outweigh genotyping costs for Dutch 
depressed patients in clinical psychiatry. MethOds: First, a decision-tree was 
created to model the first weeks of nortriptyline therapy. In the model, costs of 
hospitalization, therapeutic drug monitoring, and drug costs were captured. Based 
on the patients genetics, patients were distributed among three health states: cor-
rectly, sub-, or supra-therapeutically dosed. Utilities for each of these health states 
and at different points in time were obtained from an expert opinion (nine clini-
cians). Second, an improvement in sub or supra-therapeutically dosed patients to 
correctly dosed patients, was simulated, assuming genotyping would prevent under 
or overdosing. In the base case the improvement was 36%. In addition, we assumed 
genotyping could reduce hospitalization days with a maximum of 3.7 days (aver-
age: 28.6 days). Results from the model without genotyping were compared with 
the genotyping model. In a scenario analyses we varied the effects of genotyping 
to reach cost-effectiveness at € 20 000/quality adjusted life year (QALY) or € 50 000/
QALY. In a univariate sensitivity analysis, effects of lowering genotyping costs were 
examined. A probabilistic sensitivity analysis (PSA) was performed to investigate 
influence of parameter uncertainty. Results: In the base case, the incremental 
cost-effectiveness ratio (ICER) was € 32 697/QALY. For an ICER of € 20 000/QALY, a gen-
otyping facilitated improvement of 45% was needed and for € 50 000/QALY this was 
27%. Lowering the genotype price to € 162 made genotyping cost-saving. Results of 
the PSA indicated a probability of 0.95 for a willingness-to-pay threshold of € 46000/
QALY. cOnclusiOns: Genotyping could be cost-effective and even be cost-saving 
when genotyping costs drops. However, there is a need for more clinical evidence 
to support assumptions made in this model.
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Objectives: The purpose of this study was to develop the econometric model 
predicting the non-prescription medicines expenditure at community pharmacies 
in Malaysia MethOds: This study used data from 2009 Non-Prescription Medicines 
Utilization among Community Pharmacy Patrons in Malaysia (COMPACT1) and Sales 
of Non-Prescription Medicine in Community Pharmacy Malaysia (COMPACT2). The 
prices of non prescription medicines (NPM) in 2009 were updated to prices of 2014, 
based on Malaysian Consumer Price Index. There were four major components in 
the empirical model namely; socio-economic characteristics, health status, utili-
zation behavior and community pharmacy data. The dependent variable was the 
logarithm function of expenditure for purchasing the NPM. Ordinary least square 
method on cross-sectional data was used to predict model of NPM among com-
munity pharmacy patrons. Results: Twenty two percent (22.3%) of variation in 
NPM expenditure was explained by socio-economic characteristics, health status, 
utilization behavior, and community pharmacy data. Age, female, living at urban 
area, and had monthly household income more than RM3000 per month (~USD850) 
were found to have linear positive relationship with money spent. Those custom-
ers who had problem in pain or discomfort had 0.059 units lesser in expenditure of 
NPM. Number of medicines purchased, satisfaction towards price, usage frequency 
of medicines, and the ways of product selection were among variables in utiliza-
tion behavior that had significant linear relationship with NPM. The community 
pharmacy data on the working days and percentage of customers purchasing over 
total customers in a month shows significant negative linear relationship with 
NPM expenditure. cOnclusiOns: The study had given additional insight on the 
economics of self-medication and the role of community pharmacy as supplier 
of health care. The expenditure of NPM in Malaysia can be explained by empirical 
model that includes the purchasers’ socio-economic characteristic, health status, 
NPM utilization behavior and the information regarding utilization of community 
pharmacy.
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Objectives: The medication adherence of patients using widely prescribed beta 
blockers (Atenolol and Metoprolol) in their extended and immediate release salt 
form remains unidentified. Improving medication adherence has been shown to 
reduce health care costs. Analyzing the treatment having maximum medication 
adherence could reduce overall healthcare costs, offsetting the cost of the medica-
tion itself. The objectives of this study are to 1) compare the medication adherence of 
patients prescribed with Atenolol and Metoprolol in both immediate and extended 
release forms 2) determine the difference in healthcare expenditure between those 
highly adherent to the beta-blockers under study. MethOds: Secondary data analy-
sis using the Medical Expenditure Panel Survey (MEPS) conducted by the Agency 
for Healthcare Research and Quality and the National Center for Health Statistics. 
Medication Possession Ratio (MPR) will be used to calculate the medication adher-
ence. Patients will then be divided into three categories: high adherence (80-100%), 
intermediate adherence (79%-60%), and low adherence (< 60%). Healthcare expendi-
ture will be analyzed for each medication. Healthcare expenditures will then be 
compared between those who are highly adherent to each medication. Healthcare 
costs analyzed will include ER, outpatient, inpatient visits and prescription medica-
tion payments. Results: The patients with Atenolol extended release were asso-
ciated with the lowest adherence. Patients with Metoprolol treatment were more 
adherent than those taking Atenolol (p< 0.0001). Also, within the extended release 
group, Metoprolol Succinate had a greater rate of high adherence than Atenolol 
(p< 0.001). For patients with high medication adherence, the expenditure was the 
lowest for Metoprolol Succinate ($12490.33). Also, for immediate release, Metoprolol 
Tartrate has significantly lower healthcare costs. cOnclusiOns: Metoprolol is 
associated with higher adherence than atenolol. Also, the healthcare expenditure 
for Metoprolol is significantly lower than Atenolol.
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Objectives: Non-adherence to prescription medication has a significant impact 
on a patient’s health; often causing poorer health outcomes, preventable mortality 
and unnecessary utilization of healthcare services. Previous literature has been 
inconsistent as to what factors affect a patients’ adherence to prescription medi-
cation. Time preference, the extent that individuals are willing to discount future 
benefits for immediate benefits, has recently been acknowledged as a framework 
